Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy

Andrea De Giglio; Alessandro Di Federico; Eleonora Gariazzo; Giulio Metro

doi:10.1016/j.medj.2023.11.006

Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy

Med. 2024 Jan 12;5(1):1-3. doi: 10.1016/j.medj.2023.11.006.

Authors

Andrea De Giglio¹, Alessandro Di Federico², Eleonora Gariazzo³, Giulio Metro³

Affiliations

¹ Department of Medical and Surgical Sciences, University of Bologna, Via Albertoni 15, 40138 Bologna, Italy. Electronic address: andrea.degiglio2@unibo.it.
² Department of Medical and Surgical Sciences, University of Bologna, Via Albertoni 15, 40138 Bologna, Italy.
³ Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, via Dottori, 1, 06156 Perugia, Italy.

PMID: 38218173
DOI: 10.1016/j.medj.2023.11.006

Abstract

The PAPILLON trial showed that adding amivantamab to carboplatin-pemetrexed for advanced non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations is more effective than chemotherapy. Although safety concerns may arise, this study highlights the need for alternative therapeutic strategies beyond chemotherapy for this subtype of NSCLC.

MeSH terms

Antibodies, Bispecific*
Carboplatin / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
ErbB Receptors / genetics
ErbB Receptors / therapeutic use
Exons / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Pemetrexed / therapeutic use

Substances

amivantamab-vmjw
Pemetrexed
Carboplatin
ErbB Receptors
EGFR protein, human
Antibodies, Bispecific